Clinical Trial Detail

NCT ID NCT02974647
Title Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications

mature T-cell and NK-cell lymphoma

cutaneous T cell lymphoma

Therapies

Ruxolitinib

Age Groups: adult senior

No variant requirements are available.